See Also: U.S. Guidelines for HIV Testing, Prevention, and Treatment; Starting HIV Treatment; Changing Treatment Regimens; Salvage Treatment for HIV; Innovative Approaches to HIV Treatment

Selected Recent Articles

• Integrase inhibitors associated with improved viral suppression in HIV.  (September 2016, Healio)
• ViiV Begins Phase III Trial of Two-Drug HIV Regimen.  (August 2016, Poz)
• Tenofovir Levels in Blood 4-Fold Higher With TAF Than TDF.  (July 2016, TheBodyPro)
• Dolutegravir Superior in Women-Only Study.  (July 2016, TheBodyPro)
• Dolutegravir plus lamivudine dual therapy works well as initial HIV treatment.  (July 2016, AIDSmap); related coverage from MedPage Today
• Complera Non-inferior to Atripla.  (July 2016, MedPage Today)
• Darunavir plus cobicistat demonstrates safety, efficacy in younger, older patients.  (July 2016, Healio)
• Women-Only Trial Boosts HIV Combo.  (July 2016, MedPage Today)
• For Women with HIV, Triumeq Is Superior to Norvir–Boosted Reyataz Plus Truvada.  (July 2016, Poz)
• TAF, combination regimens improve outcomes in HIV, but challenges remain.  (July 2016, Healio)
• TAF-based regimen demonstrates safety, efficacy in patients with diabetes, renal impairment.  (June 2016, Healio)
• Darunavir Plus Cobicistat Works Well in Older HIV Groups.  (June 2016, Medpage Today)
• Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds.  (June 2016, TheBodyPro)
• Switching to TAF Noninferior to Continuing TDF in Double-Blind Trial.  (June 2016, TheBodyPro)
• Early results show doravirine regimen as effective as efavirenz regimen.  (March 2016, Project Inform)
• ‘Explosion of options’ in single-tablet regimens for HIV benefits patients, providers.  (March 2016, Healio)
• Switching to Emtricitabine/TenofovirAlafenamide (F/TAF) Maintains Viral Suppression with Better Bone and KidneySafety.  (February 2016, TheBodyPro); related coverage from AIDSmap and Project Inform
• Tivicay/lamivudine regimen more cost-effective than standard ART.  (January 2016, Healio)
• Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings.  (December 2015, AIDSmap)
• First TAF-based HIV regimen simplifies treatment, reduces toxicity.  Video dated December 2015, Healio)
• Another Two-Drug HIV Regimen Shows Promise.  (December 2015, Poz)
• Two-drug maintenance therapy keeps viral load suppressed and may even have advantages over traditional ART.  (November 2015, AIDSmap)
• Switching to Abacavir/Dolutegravir/Lamivudine (Triumeq) Maintains Undetectable Viral Load.  (October 2015, TheBodyPro)
• ICAAC 2015: Stribild Superior for Women; Better Safety & Efficacy of TAF.  (October 2015, Beta Blog)
• Rilpivirine + darunavir HIV maintenance regimen matches standard three-drug antiretroviral therapy.  (September 2015, AIDSmap)
• WAVES shows elvitegravir regimen beats boosted atazanavir for women with HIV.  (August 2015, AIDSmap)
• New HIV Med Doravirine Has Half of Sustiva’s Side Effect Rate.  (July 2015, Poz)
• HIV Antiretroviral Study Highlights From IAS 2015.  (July 2015, TheBodyPro)
• Early ART proves more beneficial than deferred treatment.  (May 2015, Healio)
• Solid Evidence Backing Early HIV Treatment Finally Arrives.  (May 2015, Poz)
• START trial finds that early treatment improves outcomes for people with HIV.  (May 2015, AIDSmap)
• Lower daily tenofovir dose of 150mg safe and effective in people with moderate renal impairment.  (May 2015, AIDSmap)
• Isentress causes less bone density loss than PIs.  (May 2015, Healio)
• Individual HIV Meds Are Just as Effective as Combo Pills.  (May 2015, Poz)
• Treatment outcomes no better with single tablet regimens than individual tablets.  (April 2015, AIDSmap)
• HIV Treatment Guidelines Nix Atripla as First-Line Therapy.  (April 2015, Poz)
• Ritonavir concentrations not correlated with lipid levels in people with HIV taking boosted atazanavir or boosted darunavir.  (April 2015, AIDSmap)
• Dolutegravir Shows Promise as Part of First-Line HIV Therapy.  (March 2015, Beta Blog)
• Dutch ATHENA study announces surprising results when using 3TC (lamivudine) over FTC (emtricitabine)  (March 2015, Project Inform)
• Novel HIV Prodrug Safer Than Its Predecessor.  (February 2015, MedPage Today)
• 3TC inferior to FTC in Dutch cohort but interchangeable in other studies.  (November-December HIV Treatment Bulletin)
• Equivalent efficacy with lower dose darunavir.  (November-December HIV 2014, Treatment Bulletin)
• Lower dose efavirenz effective in two studies.  (November-December HIV 2014, Treatment Bulletin)
• Sovaldi-Based Hep C Regimens Work Well in the Real World.  (November 2014, Hepmag)
• Lower CNS Side Effects, Similar Efficacy for Doravirine Vs. Sustiva.  (November 2014, Poz)
• Doravirine works as well as efavirenz with fewer CNS side-effects.  (November 2014, AIDSmap)
• Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up.  (November 2014, AIDSmap)
• Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy.  (November 2014, AIDSmap)
• Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy?  (November 2014, AIDSmap)
• Epivir and Tenofovir Appear Safe to Use During Breast-Feeding.  (October 2014, Poz)
• Significantly Less BMD Loss With HIV Therapy That Doesn’t Contain Tenofovir/Emtricitabine.  (October 2014, TheBodyPro)
• Complera Non-Inferior to Atripla and Better Tolerated, Study Finds.  (October 2014, TheBodyPro)
• NNRTIs and protease inhibitors both good for first ART, channelling affects choices.  (October 2014, AIDSmap)
• Factors Associated With 10 Years of Continuous Viral Load Suppression on HIV Treatment.  (October 2014, TheBodyPro)
• HIV Attachment Inhibitor BMS-663068 Compares Well to Boosted Atazanavir at 24 Weeks.  (October 2014, TheBodyPro)
• Sustiva (Efavirenz)-Free First-Line HIV Regimens Work Well.  (October 2014, Poz)
• New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless…  (September 2014, Journal Watch)
• HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir.  (September 2014, Poz)
• Atripla Is More Than the Sum of Its Three Parts.  (September 2014, Poz)
• Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs.  (September 2014, AIDSmap)
• 3TC or FTC monotherapy suboptimal as a bridging strategy for adolescents.  (August 2014, HIV i-Base)
• Tivicay Suppresses HIV Well, Even With Nuke Resistance.  (August 2014, Poz)
• Selzentry (Maraviroc) Fails to Best Truvada as First-Line Therapy.  (July 2014, Poz)
• Maraviroc fails to match tenofovir/emtricitabine for first-line HIV treatment.  (July 2014, AIDSmap)
• Once-Daily Maraviroc Inferior to TDF/FTC in First-Line Regimens With Darunavir.  (July 2014, NATAP)
• Maraviroc (MVC) Once Daily With Darunavir/Ritonavir(DRV/r) Compared to Tenofovir/Emtricitabine (TDF/FTC) With DRV/r: 48-Week Results From MODERN (Study A4001095)  (July 2014, NATAP)
• Virologic Failure Predictors in SECOND-LINE Trial of Raltegravir vs NRTIs. (July 2014, NATAP)
• New Kidney Risk Score System May Guide HIV Med Choices.  (April 2014, Poz)
• Isentress + Prezista Is Safe, Effective as First-Line HIV Therapy.  (March 2014, Poz)
• 3 Regimens Hold HIV in Check Without Efavirenz. (March 2014, MedPage Today)
• Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation.  (March 2014, AIDSmap)
• Raltegravir has the edge over two protease inhibitors in three-drug comparison study.  (March 2014, AIDSmap)
• Efavirenz Tops Lopinavir in Pregnancy. (March 2014, MedPage Today)
• In Battle of First-Line HIV Drugs, Raltegravir Beats Two Protease Inhibitors. (March 2014, TheBodyPro)
• Raltegravir plus boosted darunavir shown to be safe and effective for first-line ART.  (March 2014, AIDSmap)
• Raltegravir Combo Gives New Anti-HIV Alternative. (March 2014, MedPage Today)
• Efficacy and Tolerability of Atazanavir, Raltegravir, or Darunavir With FTC/TDF: ACTG A5257. (March 2014, NATAP)
• FDA OKs Switching From Stable HIV Regimen to Complera.  (December 2013, Poz)
• For women, HIV treatment based on atazanavir/ritonavir involves twice the risk of failure compared to efavirenz-containing therapy.  (December 2013, AIDSmap)
• Systematic review and meta-analysis shows equivalence of 3TC and FTC.  (November 2013, AIDSmap)
• SINGLE Study Underscores Waning of the Efavirenz Era – But Probably Just in the USA.  (November 2013, Journal Watch)
• Dolutegravir matches or surpasses other regimens for first-line HIV treatment.  (October 2013, AIDSmap)
• Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy.  (October 2013, TheBodyPro)
• Kaletra and Epivir Dual Therapy Works as Well as Triple Combo.  (October 2013, Poz)
• Racial Differences Seen in Comparison of First-Line Fixed-Dose Combinations.  (October 2013, TheBodyPro)
• Cenicriviroc Shows Good Virologic Success, Tolerability Compared to Efavirenz.  (October 2013, TheBodyPro)
• Eviplera works well regardless of viral load or CD4 count, may improve lipid levels.  (October 2013, AIDSmap)
• Stribild is effective and well tolerated in older people with HIV.  (October 2013, AIDSmap)
• Single-tablet regimen improves antiretroviral adherence and reduces hospitalisation.  (September 2013, AIDSmap)
• Switching from Atripla to Eviplera reduces central nervous system side-effects.  (September 2013, AIDSmap)
• New Tenofovir Has Lower Dose, Is Kinder to Kidneys and Bones.  (September 2013, Poz)
• New tenofovir formulation works equally well with less effect on kidneys and bones.  (September 2013, AIDSmap)
• Raltegravir is a good choice for people with HIV undergoing cancer chemotherapy.  (September 2013, AIDSmap)
• Quad Pill Measures Up to Two Other HIV Drug Regimens.  (July 2013, Poz)
• Making It Official: HIV Meds Have Improved Vastly.  (July 2013, Poz)
• Battle of the Integrase Inhibitors: Dolutegravir Bests Isentress.  (July 2013, Poz)
• Lower-dose lopinavir/ritonavir reduces side-effects, maintains viral control in Thai children.  (July 2013, AIDSmap)
• Studies look at bone changes during second-line therapy, fractures, and HIV- and HCV-related bone loss.  (July 2013, AIDSmap)
• First-line antiretroviral therapy has improved over time, meta-analysis shows.  (July 2013, AIDSmap)
• Dolutegravir superior to raltegravir for treatment-experienced people with HIV.  (July 2013, AIDSmap)
• Reduced efavirenz dose suppresses HIV as well as standard dose.  (July 2013, AIDSmap)